Moomoo AI 已提取核心訊息
On February 28, 2024, Tonix Pharmaceuticals Holding Corp. announced the successful completion of the clinical stage of its Phase 1 trial for TNX-1500, a potential treatment for organ transplant rejection and autoimmune diseases. The trial involved a single ascending dose escalation study of TNX-1500, an Fc-modified humanized anti-CD40L monoclonal antibody, in healthy volunteers. Results from the trial are anticipated in the third quarter of 2024. The company's CEO, Seth Lederman, highlighted the potential of TNX-1500 to improve transplant tolerance and reduce the risk of thrombosis associated with first-generation anti-CD40L mAbs. Tonix Pharmaceuticals, which focuses on developing therapeutics for central nervous system disorders and immunology, is also planning a Phase 2 trial for kidney transplant rejection prevention. The company aims to submit a New Drug Application for another candidate, Tonmya, for the management of fibromyalgia in the second half of 2024.
On February 28, 2024, Tonix Pharmaceuticals Holding Corp. announced the successful completion of the clinical stage of its Phase 1 trial for TNX-1500, a potential treatment for organ transplant rejection and autoimmune diseases. The trial involved a single ascending dose escalation study of TNX-1500, an Fc-modified humanized anti-CD40L monoclonal antibody, in healthy volunteers. Results from the trial are anticipated in the third quarter of 2024. The company's CEO, Seth Lederman, highlighted the potential of TNX-1500 to improve transplant tolerance and reduce the risk of thrombosis associated with first-generation anti-CD40L mAbs. Tonix Pharmaceuticals, which focuses on developing therapeutics for central nervous system disorders and immunology, is also planning a Phase 2 trial for kidney transplant rejection prevention. The company aims to submit a New Drug Application for another candidate, Tonmya, for the management of fibromyalgia in the second half of 2024.
2024年2月28日，Tonix Pharmicals Holding Corp. 宣佈成功完成其 TNX-1500 的1期臨床階段，該試驗是器官移植排斥反應和自身免疫性疾病的潛在治療方法。該試驗涉及在健康志願者中對一種 FC 修飾的人源化抗 CD40L 單克隆抗體 TNX-1500 的單一劑量遞增研究。該試驗的結果預計將在2024年第三季度公佈。該公司首席執行官塞思·萊德曼強調了 TNX-1500 有可能提高移植耐受性，降低與第一代抗CD40L單克隆抗體相關的血栓形成風險。專注於開發中樞神經系統疾病和免疫學療法的Tonix Pharmicals還計劃進行一項預防腎臟移植排斥反應的2期試驗。該公司的目標是在2024年下半年提交另一候選藥物Tonmya的新藥申請，用於治療纖維肌痛。
2024年2月28日，Tonix Pharmicals Holding Corp. 宣佈成功完成其 TNX-1500 的1期臨床階段，該試驗是器官移植排斥反應和自身免疫性疾病的潛在治療方法。該試驗涉及在健康志願者中對一種 FC 修飾的人源化抗 CD40L 單克隆抗體 TNX-1500 的單一劑量遞增研究。該試驗的結果預計將在2024年第三季度公佈。該公司首席執行官塞思·萊德曼強調了 TNX-1500 有可能提高移植耐受性，降低與第一代抗CD40L單克隆抗體相關的血栓形成風險。專注於開發中樞神經系統疾病和免疫學療法的Tonix Pharmicals還計劃進行一項預防腎臟移植排斥反應的2期試驗。該公司的目標是在2024年下半年提交另一候選藥物Tonmya的新藥申請，用於治療纖維肌痛。
有用
沒用